Navigation Links
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
Date:12/3/2007

sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that targets MT1 and MT2 receptors. The activity at MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) is thought to promote sleep.

*ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM(TM) should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea or in children or adolescents. The effects in these populations are unknown. Avoid taking ROZEREM with alcohol. Studies for severe COPD have not yet been evaluated by the FDA. ROZEREM has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms which could include cessation of menses or galactorrhea in females, decreased libido or problems with fertility that are possibly associated with such changes in these hormone levels. ROZEREM should not be taken with or immediately after a
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... and seek insurance rates for term or universal policies ... of some of the best life insurance companies for ... through the system at http://quotespros.com/life-insurance.html . , The ... the search portal are tied to a number of ...
(Date:3/1/2015)... York (PRWEB) March 01, 2015 ... lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to ... must prepare a witness to provide testimony regarding ... the development of the Profemur device, Bernstein Liebhard ... U.S. District Court, Northern District of Iowa on ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... ERISAPros is pleased to announce the ... professional staff of its Compliance Department. , Evelyn King, ... University-Mortiz College of Law. Prior to joining ERISAPros, Evelyn ... Fortune 500 companies as well as several privately held ... experiences range from benefit plan design, vendor management, administrative ...
(Date:3/1/2015)... California (PRWEB) March 01, 2015 Theme ... a new transition pack for Final Cut ... add accordion style transitions to any FCPX editors project.” ... given our users the tools needed to easily drag ... , The user gets many different controls over the ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2
... of a previously ischemic tissue is associated with ... in many organs including the liver. The injury ... consisting of an early stage started upon reoxygenation ... reactive oxygen species formation during reperfusion induces a ...
... and blood clots are often recommended to stop these ... polyps., However, interruption of these medications can place patients ... led by Shai Friedland at the VA Palo Alto ... polyps without interrupting anticoagulation. Their study will be published ...
... types of reconstruction of gastrointestinal continuity after gastric resection. ... how the geometry and flow conditions affect the gastroduodenal ... be the dominant cause of duodenal suture dehiscence, but ... remain unclear. , A research article to be ...
... MAResearchers at Brandeis, in collaboration with several other institutions ... economic costs of dengue fever, the endemic and epidemic ... problem in tropical and sub-tropical countries. The study, ... Journal of Tropical Hygiene , assessed the direct and ...
... Stressed about Work, Money and the EconomySeven out ... MeasuresWASHINGTON, May 7 Economic pressures are having ... 54, according to a new survey by the ... men are reporting significant stress related to work, ...
... The Board of Directors of Tyco International Ltd. (NYSE: ... 0.23 Swiss Francs (CHF) per share, payable on August 26, ... on July 31, 2009, subject to a required filing with ... share is the second installment of an annual dividend of ...
Cached Medicine News:Health News:A new light on the mechanisms of early stage liver reperfusion injury 2Health News:Dengue fever costs billions in health care, lost productivity and absenteeism 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... 2015  In recognition of Rare Disease Day and ... bleeding disorders community, CSL Behring announced today ... of protein therapies to the World Federation of Hemophilia ... has worked to improve the lives of people with ... the WFH,s Global Alliance for Progress (GAP) Program aimed ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3
... BARRX Medical Inc., a leader in the ... precancerous tissue from within the gastrointestinal tract, reported today ... (SAGES) has issued a new practice guideline for the ... reflux of stomach contents such as acid and bile ...
... , SAN FRANCISCO , June 1 ... to continue on FIRMAGON® (degarelix for injection) after one ... according to results of a Phase III extension study(1) ... PSA is commonly used in monitoring prostate cancer patients, ...
Cached Medicine Technology:The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 2The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 3The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
... System combines Invivo's AutoNet™ wireless networking ... and clinical information system (CIS) features. ... including alarms, full disclosure and vital ... patient to a bedside monitor or ...
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... The Alaris System integrates drug ... practice guidelines,into a single, modular platform. ... or remove modules as you,need them, ... the bedside,to a minimum while managing ...
Medicine Products: